NAUT

NAUT is extending Voyager from tau into oncology, which I think will give it more applications for its targeted proteoform platform. NAUT also has research collaborations and SEEDS participation. In my view, this corroborates that there's real scientific interest in their platform. Management's runway projection should be enough to reach their planned launch of Voyager instruments and initial assay kits.

Nautilus Biotechnology, Inc. (NAUT) Q3 2026 Earnings Call Transcript

Nautilus Biotechnology NASDAQ: NAUT reported third-quarter revenue of $200,000 as it continued its transition toward commercialization of its Voyager proteomics platform, with management reaffirming plans to begin taking platform pre-orders in early 2027 and start instrument shipments in mid-2027.

Nautilus expects to receive up to $6 million to bring its Voyager™ Platform to a multidisciplinary team integrating protein science, AI, and computational modeling to develop new diagnostics and therapeutics Nautilus expects to receive up to $6 million to bring its Voyager™ Platform to a multidisciplinary team integrating protein science, AI, and computational modeling to develop new diagnostics and therapeutics

SEATTLE, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2026.

SEATTLE, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the third quarter 2026 before market open on Tuesday, October 27, 2026.

First large-scale, single-molecule analysis of the tau proteoform landscape reveals unique disease-associated modifications, a new source of potential biomarkers and drug targets, and a method Nautilus is now extending across disease areas First large-scale, single-molecule analysis of the tau proteoform landscape reveals unique disease-associated modifications, a new source of potential biomarkers and drug targets, and a method Nautilus is now extending across disease areas

NAUT is now prioritizing targeted proteoform assays after Broadscale testing failed to support its prior commercialization roadmap. But their roadmap with Voyager is clearer, although Early Access revenue remains too limited to prove it can turn into recurring sales. Unfortunately, the main risks going forward are still tied to potential execution setbacks, its ongoing cash burn, and a likely capital raise by 2027.

Nautilus Biotechnology NASDAQ: NAUT said it is shifting a significant share of its research and development resources toward proteoform applications, citing customer interest and a delay in its Broadscale broad-proteome program.

SEATTLE, July 28, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the second quarter ended June 30, 2026. Second Quarter 2026 Business Highlights Recognized first revenue in the second quarter of 2026, including grant revenue from the Michael J.